FY2026 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of $0.28 for the year, up from their prior forecast of ($0.52). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.85) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2027 earnings at ($0.14) EPS, FY2028 earnings at $0.59 EPS and FY2029 earnings at $1.21 EPS.

RGNX has been the subject of a number of other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. Morgan Stanley restated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of REGENXBIO in a report on Wednesday, January 15th. Raymond James restated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Chardan Capital restated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and an average target price of $34.82.

REGENXBIO Price Performance

Shares of RGNX opened at $8.07 on Monday. REGENXBIO has a 1 year low of $6.56 and a 1 year high of $28.80. The stock has a 50 day simple moving average of $8.23 and a two-hundred day simple moving average of $10.19. The firm has a market cap of $399.83 million, a P/E ratio of -1.60 and a beta of 1.28.

Institutional Trading of REGENXBIO

Institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC grew its position in shares of REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after buying an additional 323,100 shares during the period. Assenagon Asset Management S.A. lifted its position in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after acquiring an additional 296,700 shares during the period. Millennium Management LLC boosted its stake in REGENXBIO by 84.8% during the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock worth $3,586,000 after acquiring an additional 140,666 shares in the last quarter. National Bank of Canada FI purchased a new stake in REGENXBIO in the third quarter worth about $713,000. Finally, Barclays PLC increased its stake in shares of REGENXBIO by 141.3% during the third quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after purchasing an additional 67,948 shares in the last quarter. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.